Quantcast

Latest Bcl-2 Stories

2009-06-29 09:47:25

A research article to be published on June 21, 2009 in the World Journal of Gastroenterology addresses this question. The research team led by Professor Yan Li from Shengjing Hospital of China Medical University studied the growth inhibitory effects of Alisol B acetat and determined its mechanism of antitumor activity in human gastric cancer cell line SGC7901.Professor Li and his colleagues found that Alisol B acetat could inhibit the proliferation of SGC7901 cell in a time and dose dependent...

2009-05-26 07:00:00

MALVERN, Pa., May 26 /PRNewswire/ -- Ascenta Therapeutics announced today that eleven presentations or publications on pre-clinical and clinical studies of AT-101, an oral, pan-Bcl-2 inhibitor, in several major tumor types will be made during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, in Orlando, Florida. Abstracts are available at www.asco.org. (Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO ) Prostate Cancer MacVicar G, et al....

2009-05-22 10:19:52

Looking for efficient anti-tumor drugs is a hot research area. Chrysin (5,7-dihydroxy flavone), a natural widely-distributed flavonoid, has been reported to have many different biological activities such as anti-oxidant, anti-virus, antidiabetogenic activity and clear anxiolytic effect. However, Chrysin is limited in its clinical application because of its modest absorption in the intestine and rapid in vivo glycosylation. To improve the biological activity of chrysin, a number of its...

2009-04-21 09:00:00

- Data on novel pro-apoptotic agent presented at the 100th Annual Meeting of the American Association for Cancer Research - - University of Pennsylvania data on chemotherapy resistance patterns in neuroblastoma cell lines, highlighting AT-101's inhibition of Mcl-1, also presented - MALVERN, Pa., April 21 /PRNewswire/ -- Ascenta Therapeutics announced today that the results of preclinical studies of its orally-active, small molecule, pro-apoptotic agent, AT-406, have been presented at the...

2009-04-16 13:52:19

A protein called Mcl-1 plays a critical role in melanoma cell resistance to a form of apoptosis called anoikis, according to research published this week in Molecular Cancer Research.The presence of Mcl-1 causes cell resistance to anoikis. This resistance to anoikis enables the melanoma cells to metastasize and survive at sites distant from the primary tumor, according to Andrew Aplin, Ph.D., an associate professor of Cancer Biology at Jefferson Medical College of Thomas Jefferson University,...

2009-03-03 08:35:00

Knowledge of mitochondrial processes could aid understanding of neurodegenerative diseaseMitochondria are restless, continually merging and splitting. But contrary to conventional wisdom, the size of these organelles depends on more than fusion and fission, as Berman et al. show. Mitochondrial growth and degradation are also part of the equation.The study will appear online March 2, 2009 (www.jcb.org) and in the March 9, 2009 print issue of The Journal of Cell Biology (JCB).Fission is...

2009-02-27 10:45:00

- Data presented today at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium - MALVERN, Pa., Feb. 27 /PRNewswire/ -- Ascenta Therapeutics announced today positive preliminary results from its Phase II study of AT-101 in combination with docetaxel and prednisone (D/P) in men with docetaxel refractory, castrate resistant prostate cancer (CRPC) at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, FL. AT-101, an oral,...

2009-01-16 16:25:15

Singapore scientists report findings in Molecular CellResearchers at A*STAR's Institute of Molecular and Cell Biology (IMCB) have become the first to discover and characterize a human protein called Bax-beta (BaxÃŽ²), which can potentially cause the death of cancer cells and lead to new approaches in cancer treatment. The finding is published in the 16 Jan. report of Molecular Cell.Detection of BaxÃŽ² has eluded scientists until now. Said Dr Victor Yu,...

2008-10-31 09:00:08

Gemin X Pharmaceuticals announced today that clinical data from a Phase 1/2 study of obatoclax (GX15-070), the Company's innovative pan Bcl-2 inhibitor, will be presented during The 26th Chemotherapy Foundation Symposium being held in New York City from November 4 - 8, 2008. Program Title: Phase 1/2 Study Of Docetaxel Plus Obatoclax in Relapsed NSCLC Presenter: Alberto A. Chiappori, MD Assistant Member Thoracic Oncology, Experimental Therapeutics H. Lee Moffitt Cancer...

2008-10-30 21:00:11

Pre-clinical studies presented at the 9th International Conference on Membrane Redox Systems in Wellington New Zealand this week demonstrate that Novogen's NV-128 (a novel mTOR inhibitor), when used in combination with the Marshall Edwards, Inc.'s Phase III anti-ovarian cancer drug, phenoxodiol, produces potent synergistic anti-cancer activity against non-small cell lung carcinoma cell lines (NSCLC). Importantly, the synergistic cytotoxicity observed between NV-128 and phenoxodiol was...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related